Recently closed projects/recent gesloten projecten/projets récemment fermés/kürzlich geschlossene Projekte

Protocol EORTC 62024: Intermediate and high risk localized, completely resected, gastrointestinal stromal tumors (GIST) expressing KIT receptor: a controlled, randomized trial on adjuvant imatinib mesylate (Glivec) versus no further therapy after complete surgery. Study group/sponsor: EORTC. Contact: Prof. Dr. P. Schöffski

Ongoing projects/lopende projecten/projets actifs/laufende Projekte

Protocol CSTI571X2101: A multi-arm, dose-finding phase Ib multicenter study of imatinib in combination with the oral phosphatidyl 3-kinase (PI3-K) inhibitor BKM120 in patients with gastrointestinal stromal tumor (GIST) who failed prior therapy with imatinib and sunitinib. Study group/sponsor: Novartis. Contact: Prof. Dr. P. Schöffski. For further information, please visit the website www.cancertrials.be.

Protocol CSTI571X2103: A dose-finding phase Ib multicenter study of imatinib in combination with the oral phosphatidyl-inositol 3-kinase (PI3K) inhibitor BYL719 in combination with gastrointestinal stromal tumor (GIST) who failed prior therapy with imatinib and sunitinib. Study group/sponsor: Novartis. Contact: Prof. Dr. P. Schöffski. For further information, please visit the website www.cancertrials.be.

Planned projects/geplande projecten/projets en développement/geplante Projekte

Protocol EORTC 1317-STBCSG: Phase II study of cabozantinib in patients with gastrointestinal stromal tumor (GIST) who progressed during neoadjuvant, adjuvant or palliative therapy with imatinib and sunitinib. Study group/sponsor: EORTC. Contact: Prof. Dr. P. Schöffski. For further information, please visit the website www.cancertrials.be.